KLP Kapitalforvaltning AS Has $57.90 Million Stake in Thermo Fisher Scientific Inc. $TMO

KLP Kapitalforvaltning AS boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,683 shares of the medical research company’s stock after purchasing an additional 5,600 shares during the period. KLP Kapitalforvaltning AS’s holdings in Thermo Fisher Scientific were worth $57,904,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. RMG Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter worth about $131,000. Hardy Reed LLC boosted its position in Thermo Fisher Scientific by 96.9% during the 2nd quarter. Hardy Reed LLC now owns 5,060 shares of the medical research company’s stock worth $2,052,000 after acquiring an additional 2,490 shares during the last quarter. Roberts Wealth Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 3.9% during the 2nd quarter. Roberts Wealth Advisors LLC now owns 8,625 shares of the medical research company’s stock worth $3,497,000 after acquiring an additional 321 shares in the last quarter. KPP Advisory Services LLC raised its holdings in shares of Thermo Fisher Scientific by 10.4% in the second quarter. KPP Advisory Services LLC now owns 4,159 shares of the medical research company’s stock valued at $1,686,000 after purchasing an additional 391 shares during the last quarter. Finally, Wormser Freres Gestion lifted its position in shares of Thermo Fisher Scientific by 35.7% in the second quarter. Wormser Freres Gestion now owns 20,793 shares of the medical research company’s stock worth $8,428,000 after purchasing an additional 5,475 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $544.44 on Tuesday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a market cap of $205.59 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The business’s 50 day moving average price is $483.77 and its two-hundred day moving average price is $446.95. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company posted $5.37 EPS. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TMO. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.